DUBLIN, Ireland—Allergan plc (NYSE: AGN), a leading global pharmaceutical company based here, has entered into a definitive agreement with Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH) in which Allergan has agreed to acquire Kythera in a cash and equity transaction valued at $75 per Kythera share, or approximately $2.1 billion, subject to the fulfillment of certain customary conditions. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new AGN shares issued to Kythera shareholders.

“The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth,” said Brent Saunders, CEO and president of Allergan. This follows the high-profile acquisition of Allergan by Actavis, as reported by VMail.